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SV is a major cause of morbidity and mortality world-
wide. Although no treatment or vaccine currently ex-
ists, RSV therapeutics and preventative strategies are 
being evaluated in clinical trials, including phase 3 trials. De-
spite great prospects, the regulatory pathways of novel RSV 
therapeutics have been defined insufficiently. Here we report 
the results from the ReSViNET 2nd High–level expert meet-
ing 2016 on RSV therapeutics, which was held in Zeist, the 
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Netherlands on March 2nd and 3rd. This meeting was orga-
nized to advance discussion on regulatory pathways, clinical 
development, clinical trials, and health technology models 
in the RSV therapeutics field. During this meeting regulators, 
public health specialists, academia, non–governmental or-
ganizations and pharmaceutical companies openly discussed 
and addressed the needs for the successful development of 
RSV therapeutics and prophylaxis.
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THE NEED AND THE OPPORTUNITY
RSV infection is one of the leading causes of acute lower 
respiratory infection (ALRI) related hospitalization and 
mortality during early childhood [1]. The current burden 
estimates are based on limited data. To overcome this data 
gap and to inform policy for introduction of RSV vaccine 
(which appears likely in the next 5–7 years), the Bill and 
Melinda Gates Foundation (BMGF) funded the RSV Glob-
al Epidemiology Network (RSV GEN), a platform to bring 
together RSV researchers from low and middle income 
countries to share unpublished data from ongoing / recent-
ly completed studies. This network has contributed data 
from more than 75 sites for the revised RSV burden esti-
mates for 2015 which were presented at the meeting by Dr 
Nair. It is anticipated that these results which are of huge 
interest to clinicians, donor agencies and policy makers will 
be published soon.
The 2016 ReSViNET meeting aimed to discuss the devel-
opment of different RSV therapeutics, the existing hurdles 
and strategies to overcome these barriers. Dr Ramilo pro-
vided an overview of the different target populations for 
therapy against RSV–infection. Current therapies are lim-
ited to specific populations. Prophylaxis with anti–RSV 
monoclonal antibodies is directed to high–risk populations 
only including preterm infants, children with bronchopul-
monary dysplasia and those with congenital heart disease 
(CHD), as well as selected children with cystic fibrosis (CF) 
and immunocompromised conditions. However, the great 
majority of patients with RSV infection including children 
hospitalized with severe lower tract infection, and those 
with mild disease managed as outpatients are treated symp-
tomatically. Not much is known yet about the burden of 
RSV disease among the elderly and in individuals with 
Chronic Obstructive Pulmonary Disease (COPD) and there 
are no RSV–specific therapies for these individuals. Ramilo 
gave a review of vaccines in development, mentioning the 
pros and cons of the different vaccines strategies and he 
also introduced antivirals and monoclonal antibodies 
(Mabs) in clinical development [2]. In the presentation, the 
need to optimize the design of clinical studies aimed at de-
veloping both treatment and preventive strategies against 
RSV was discussed. He reviewed how to best select the pa-
tient populations and the clinical context to evaluate the 
different interventions, to define clinical endpoints, and 
how to put into practice the lessons that can be learned 
from the development of antiviral therapy for HIV or from 
the vaccines against pneumococcus. For defining and 
adapting clinical endpoints, Ramilo outlined challenges as 
well as opportunities and emphasized the importance of 
obtaining robust and comprehensive clinical data, because 
society wants the interventions to be cost–effective. Finally, 
Ramilo showed the importance of selecting laboratory 
markers, virologic as well as immune markers and encour-
aged the participants to incorporate collection of clinical 
samples in their clinical trials to facilitate laboratory analy-
ses that permit a better understanding of how interventions 
work (or not) against RSV infection.
REGULATORY CONSIDERATIONS IN 
INITIATING PAEDIATRIC CLINICAL 
TRIALS FOR RSV THERAPEUTICS
Overview of pediatric development plans 
evaluated by Paediatric Committee PDCO: 
regulatory considerations for initiating 
pediatric trials
Dr Eichler gave an overview of Paediatric Investigation Plans 
(PIPs) for RSV–antivirals and monoclonal antibodies for 
which the information is available in the public domain. 
Main challenges for the PDCO of the European Medicines 
Agency (EMA), responsible for assessing the content of Pae-
diatric investigation plans, are the current lack of generally 
agreed recommendations by the scientific community re-
garding when to best initiate antiviral treatment, and the lack 
of validated and agreed clinically meaningful outcome mea-
sures for evaluating the effect of RSV antivirals.
Upper respiratory tract infections caused by RSV are not 
considered a major clinical problem, necessitating antiviral 
treatment. However, in children at high risk for severe low-
er respiratory disease (LRD) caused by RSV, the initiation 
of antiviral treatment early in course of RSV infection, ie, 
before major tissue injury in the lower airways has oc-
curred, could benefit them to prevent severe LRD. At pres-
ent, clear definitions for bronchiolitis and/or severe LRD 
are lacking.
The highest disease burden is considered in the first 2 years 
of life; consequently, this age cohort should be included in 
clinical trials [3]. It would be desirable to also evaluate the 
efficacy and safety of antivirals in older children at high risk 
to develop serious RSV LRD, ie, children with chronic un-
derlying conditions, such as immunodeficiency or neuro-
muscular disease. As these populations are very heteroge-
neous and small, the conduct of dedicated clinical studies 
in these populations is most likely not feasible. At present, 
it is unknown to what extent extrapolation of efficacy is 
possible from young children in whom severe RSV infec-
tion manifests clinically as bronchiolitis to older children 
with underlying chronic diseases, in whom RSV infections 
manifest as RSV pneumonia. Therefore, the generation of 
limited clinical data in older children with chronic under-
lying conditions needs to be discussed.
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In the absence of validated endpoints, a consensus defini-
tion of a set of core outcome measures which should be 
measured and reported in all clinical trials is highly war-
ranted to allow comparability of trial results and to validate 
candidate endpoints.
Regulatory aspects related to development 
of vaccines for RSV
Dr Pelfrene outlined the main regulatory considerations for 
maternal immunization and subsequent determination of 
protective efficacy in the offspring, the primary vaccination 
in infants as well as the desired safety database and duration 
of safety follow–up for both strategies. Foremost was stressed 
that the trial sponsor should define the intended aim of vac-
cination, since ultimately this will inform the labeling claim, 
ie, prevention of a specific clinical presentation. The case 
definition for RSV disease will require subjects to meet both 
clinical and laboratory criteria [4]. In this regard, it was em-
phasized that specific and sensitive assay methods for detec-
tion of RSV breakthrough cases should be employed in a 
standardized manner across participating study centers. The 
need and feasibility of a central laboratory confirmation 
should also be determined. Study protocols will need to de-
fine and justify the method of specimen collection (eg, na-
sopharyngeal aspirate or nasal swab) and provide details on 
sample storage and shipping conditions.
With respect to vaccination during pregnancy, it was stated 
that background rates of fetal demise, prematurity and con-
genital aberrations need to be available. Prior to conducting 
clinical trials in pregnant women, demonstration of safety 
and immunogenicity data in healthy adults (including non–
pregnant women) will be necessary, as well as favorable pre-
clinical data to be obtained on immunology and toxicology, 
including experiments performed in late stage pregnant an-
imals. Exploratory trials may provide sufficient data on 
trans–placental transfer and persistence of maternal anti-
bodies in the infant. In this sense, it is recognized that du-
ration of protection may be trial setting dependent and a 
function of antibody titer at birth and rate of decline in the 
infant. Efficacy trials are expected to be broadly inclusive 
but there will likely be a need to stratify or to exclude sub–
groups with recognized poor trans–placental transfer, such 
as HIV infected subjects. For the confirmatory trials, due 
consideration should be given to seasonality: immunization 
in 3rd trimester pregnancy will need to be scheduled with-
in an appropriate time–window so that ensuing delivery 
coincides with the early part of the RSV season. With regard 
to infant immunization, it was stressed that the aim would 
be to elicit a strong neutralizing antibody response with a 
non–T helper type 2 (Th2) biased cellular immune re-
sponse. Vaccine development strategy will most probably 
be featuring an age–de–escalation approach, and thus first 
be administered to RSV seropositive adults and children be-
fore progressing to RSV–naïve infants. The question of op-
timal timing of immunization was raised, with primary se-
ries to start as early as feasible in infancy, taking into account 
the inhibitory effect of maternal antibodies. In the case of 
vaccinating infants born to vaccinated mothers, the estimate 
of duration of passive protection should be known before 
deciding when to start active immunization. Further on, it 
was conveyed that the current EU general expectation re-
garding a pre–licensure safety database for a novel vaccine 
is a minimum of 3000 exposed persons to the final dose 
regimen of the vaccine. Though, for the vaccination of in-
fants, it needs to be discussed what the breadth of evidence 
should be, to support negligible risk of disease enhance-
ment in the RSV–naïve population.
During the discussion, it was acknowledged that the major 
RSV burden and mortality occurs in low–income countries. 
As such, it was asserted that ideally, vaccine– and therapeu-
tic development programs need to consider a global per-
spective. Hence, it would be desirable that case definitions 
include clinical features which are easily standardized and 
generalizable across the different settings. EMA urged the 
use of the same scoring systems or scales in the trials and 
meeting participants were encouraged to consider scien-
tific qualification advice for potential candidate biomark-
ers/outcome measures.
MEASURING SAFETY
Assessing the impact of anti–RSV 
interventions: clinical endpoints and 
biomarkers
It is possible to combine clinical endpoints to evaluate anti–
RSV interventions with viral factors, host immune profiles 
and antibody responses for the diagnosis, pathogenesis and 
assessment of RSV disease severity [5]. Dr Mejias discussed 
that as age goes up, a decrease of antibodies against RSV 
are seen in the infant, acutely infected with RSV, reflecting 
maternal antibody transfer. Having measured neutralizing 
activity, they didn’t find a perfect correlation between con-
centration and neutralization, which needs to be under-
stood. In fact, standardizing antibody assays and identify-
ing a consistent antibody threshold indicative of protection 
still needs to be defined. However, Mejias made clear that 
other biomarkers such as genomics markers have a great 
value as predictive tools and to objectively assess disease 
severity. The team formed by Mejias and Ramilo found in 
infants hospitalized with RSV bronchiolitis significant cor-
relations between a molecular genomic score and (1) the 
clinical disease severity score, (2) duration of hospitaliza-
tion and (3) duration of supplemental oxygen. They are 
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now using these tools to understand responses to thera-
peutic interventions, to monitor disease progression as well 
as to study the normal maturation of the immune system 
in infants. Furthermore, in collaboration with Dr Bogaert, 
Mejias studied the role of bacterial colonization on RSV 
disease severity, and noticed that nasopharyngeal bacterial 
colonization with specific pathogens did not appear to be 
a passive phenomenon. Specifically, infants with RSV infec-
tion and colonized with S. pneumoniae or non–typable H. 
influenzae displayed a more severe clinical phenotype and 
different host transcriptional profiles. Understanding the 
RSV–bacterial interactions in these children is of key im-
portance when evaluating the benefit of RSV therapeutics. 
The challenge consists of developing composite endpoints 
that include clinical, virologic and laboratory parameters 
to monitor responses to clinical interventions.
Enhanced RSV disease and vaccines
There are a number of new strategies for RSV vaccines, 
mentioning that each formulation may present individual 
characteristics that theoretically decrease or increase the 
risk for enhanced RSV disease (ERD) [6]. Dr Polack dis-
cussed ERD, which has been seen only in sero–negative 
infants and young children who were previously immu-
nized with a formalin inactivated RSV vaccine. For many 
years, the consensus was that nothing but live attenuated 
RSV vaccines would ever be used to immunize infants. 
Therefore, the characterization of ERD phenotypes was of 
academic interest but had limited regulatory implications. 
Based on the outcome in mice studies and limited human 
data, it may be assumed that it is worthwhile to look for 
Th2 endpoints. However, there is a need for a consensus 
definition of Th2 bias and/or a consensus set of control 
groups for studies. ERD does not impact sero–positive chil-
dren, because better antibodies precede immunization. Po-
lack told the audience not to rely on older subjects in phase 
1 studies, since there is no ERD in patients that had RSV 
infection before, so that would prove to be futile.
Polack concluded that the monoclonal antibodies and ma-
ternal immunization strategies are safe. For other vaccines, 
awareness of steric hindrance is needed and he suggested 
waiting between immunization and challenge, because of 
the danger of misunderstanding the read out. In summary, 
Polack said that RSV vaccines should elicit a long–lived 
protective antibody of high avidity for RSV protective an-
tigens and specific cytotoxic T lymphocytes, and, neither 
elicit lung eosinophils, nor bias the response to Th2.
During the discussion, the participants discussed how to 
measure low affinity antibodies in the clinical setting, and 
how to assess the risk for developing ERD. How to use the 
information for vaccine studies was food for thought, since 
a perfect model of ERD is lacking. Dr Polack stressed that 
if ERD occurs, it probably will manifest in many individu-
als, as early trials had disease rates above 50%.
RSV COST EFFECTIVENESS AND 
EPIDEMIOLOGY
RSV vaccine in development: assessing the 
potential cost–effectiveness in high risk 
adult populations
The potential cost–effectiveness of RSV vaccination in high 
risk adults was discussed, with a main focus on the elderly 
population. Dr Pouwels noted the importance of thinking 
about the target population, when evaluating vaccines. The 
most obvious choice would be infants, given the well–es-
tablished burden among infants. However, there is accu-
mulating evidence that RSV causes a substantial burden in 
high–risk adults and elderly [7]. To date, two health eco-
nomic studies that evaluated vaccination of the elderly 
against RSV have been published [8,9]. Both studies indi-
cated that vaccination of the elderly has the potential to be 
cost–effective, especially among high–risk elderly. Howev-
er, both studies were performed with limited data about 
the burden of RSV among the elderly. Moreover, one of the 
main drivers of the successes of several vaccination cam-
paigns–indirect protection by reducing transmission–was 
not taken into account. Hence, there is a need for an up-
dated transmission dynamic cost–effectiveness model to 
evaluate which vaccination strategy is most cost–effective. 
A recent transmission dynamic model from Kenya, which 
did not focus on the elderly population, concluded that 
vulnerable infants could be indirectly protected by annual 
vaccination of all school–age children [10]. Another study 
from the same region, estimated that it may be sufficient to 
vaccinate children aged 5–10 months [11]. It is clear that 
more models, also incorporating direct and indirect protec-
tion of the elderly, are needed. Pouwels concluded that to 
assess the impact and cost–effectiveness of the different 
strategies using transmission dynamic models, better age–
group specific virological surveillance and more data on 
the age– and risk–group specific burden are needed.
Collaboration to conduct research on 
vaccine preventable diseases in Canada–
what we are learning
The Canadian Immunization Research Network (CIRN; 
http://cirnetwork.ca/) includes a hospital–based surveil-
lance network (Serious Outcomes Network) which evalu-
ates morbidity associated with vaccine–preventable infec-
tions (eg, influenza) and vaccine efficacy in adults. CIRN 
collaborates with the Immunization Monitoring Program 
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ACTive (IMPACT) which conducts similar research as well 
monitoring adverse events following immunization, in pe-
diatric health centers [12]. Dr Langley noted that these net-
works could be of interest to the RSV field for determining 
the burden of disease. The supportive networks within 
CIRN, Social Sciences and Humanities Network, Reference 
Laboratory Network, and Modeling and Economic Re-
search Network actively take part in study design the stud-
ies [13]. The focus of CIRN’s work is vaccine safety, immu-
nogenicity and effectiveness, vaccine coverage, vaccine 
hesitancy, and program implementation and evaluation. 
IMPACT started a working group on RSV in 2015, looking 
at what is available on Canadian epidemiology and plan-
ning for a surveillance project on severe outcomes in hos-
pitalized children. These networks have found that trans-
parent, open processes, standard operating procedures for 
study processes, project review and funding of have been 
essential in conducting research in multiple provinces 
across a large country.
The discussion was based on the influenza surveillance 
data generated by these networks, including the studies 
controlling for frailty in older persons. The need for sig-
nificantly more data to make the right cost–effective mod-
els impressed the audience, but the overall expectation was 
that in a year, based on CIRN and other studies of RSV ill-
ness in the community, there will be more sophisticated 
models available to accurately assess this burden.
During the discussion it was emphasized what we can learn 
from a recent transmission dynamic cost–effectiveness 
model that led to the decision to extend influenza vaccina-
tion to children in the UK. A lot more data are needed to 
build a similar model for RSV vaccination, both in terms 
of better age–specific RSV virological surveillance, short– 
and long–term consequences of RSV infection among dif-
ferent age–groups, and the effect of vaccination on trans-
missibility of RSV. Meanwhile, cost–effectiveness models 
should be updated when clinical trial data and improved 
burden of disease estimates become available in the near 
future.
DEVELOPMENT OF RSV VACCINES FOR 
USE IN PREGNANCY
Clinical endpoints in trials of RSV vaccines 
in pregnant women: study design issues, 
assessment of safety and effectiveness
Maternal influenza studies were discussed as a comparator 
for vaccination of pregnant women against RSV. Dr Nunes 
discussed the challenges for maternal immunization espe-
cially in low– and middle–income countries (LMIC), and 
identified assessing the accurate gestational age as a main 
problem. The best method would be early ultra sound, 
which is not always available. Nunes emphasized the im-
portance to know the study population for designing such 
a trial and gave examples of risk–factors which are more 
prevalent in LMIC such as co–morbidities like anemia and 
concomitant illnesses (HIV, malaria) that may affect the pla-
cental function. For experimental vaccines a randomized, 
placebo–controlled trial would be the desired study design, 
with a primary objective of evaluating the efficacy of RSV 
vaccination of pregnant women against laboratory–con-
firmed RSV LRTI in their infants up to 3 months of age. A 
major concern in maternal immunization trials is safety 
endpoints; in this regard the WHO requested the Brighton 
Collaboration (BC) to develop a guidance document har-
monizing safety assessments during maternal and neonatal 
vaccine trials in all resource settings ie, in LIC and high IC. 
Although promising, maternal vaccination might be limited 
by transplacental antibody transfer, antibody decay rates in 
the infants and safety in pregnant women. Information on 
RSV–associated disease burden in pregnant women is lack-
ing and will be obtained from virological analyses from the 
recent large maternal influenza vaccine trials.
Lessons learned from non–RSV maternal 
immunization – safety, immunogenicity 
and effectiveness
Safety of maternal vaccination was discussed by Dr Van der 
Maas. She mentioned that based on the monitoring in a 
Norwegian influenza immunization study after the influ-
enza A (H1N1) pandemic in 2009, no increased risk was 
found for fetal death in vaccinated women compared to 
non–vaccinated women, but women who contracted influ-
enza during pregnancy did have a significantly greater risk 
of fetal death compared with pregnant women who did not 
suffer from influenza [14]. It was concluded that vaccina-
tion works and is safe, backed by other papers and a Dutch 
study. Follow up of the infants up to 1 year showed no dif-
ference for growth, development and GP infection–related 
contact rates, in infants of vaccinated and non–vaccinated 
mothers [15–17]. Furthermore, Van der Maas referred to 
the re–emergence of pertussis in the world, and empha-
sized the importance of monitoring the maternal pertussis 
vaccination for effectiveness, immunogenicity and safety. 
Regarding immunogenicity and the transplacental IgG 
transport, the timing of the vaccination is crucial. One of 
the lessons learned from non–RSV maternal vaccination is 
the essential monitoring of safety, effectiveness and immu-
nogenicity, in order to maintain the public trust, the occur-
rence of disease in infants (“vaccine failure” vs “failure to 
vaccinate”), and to optimize the infant and maternal vac-
cination schedule.
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It was discussed that the most common cause of non–ob-
stetrical fatal illness in pregnant women is in fact respira-
tory disease. Another point was what would be the best 
settings for conducting trials of such a vaccine, since the 
burden is highest in populations that cannot afford private 
health care and high cost interventions. The participants 
agreed that the trials should be conducted both in devel-
oped countries and in LMIC. Besides, the BMGF has part-
nered with industry with the aim of making these vaccines 
available at a lower cost in developing countries.
Disclaimer: The views expressed in this paper are the personal views of the authors and 
must not be understood or quoted as being made on behalf of or representing the posi-
tion of the EMA or one of its committees or working parties.
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CONCLUDING REMARKS
The 2016 ReSViNET meeting was organized with partici-
pation of pharmaceutical companies, public health advo-
cates, academia, WHO, FDA, EMA and the BMGF. There 
was a focus on regulatory requirements for upcoming RSV 
therapeutics. The meeting integrated information from 
many of the stakeholders, including views of the regulators 
and public health. Alignment of the regulatory require-
ments with the developments in the pharmaceutical field 
was identified as a major challenge. Integrating the views 
of all stakeholders, including the patient’s perspective, will 
optimize the development of novel therapeutics against a 
respiratory virus which continues to cause so much disease 
to so many people worldwide.
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